The Role of Tumour Microenvironment in Cancer Progression and Therapeutic Resistance Mechanisms and Implications for Treatment Strategies

Habibah Nadeem; Muhammad Kashif Shahzad Virk; Faizan Abbas; Zahra Nawaz; Muhammad Waseel Ahmad; Musab Binyameen

doi:10.70749/ijbr.v3i4.991

Authors

Habibah Nadeem CMH Lahore Medical College and Institute of Dentistry, Pakistan.
Muhammad Kashif Shahzad Virk CMH Lahore Medical College and Institute of Dentistry, Pakistan.
Faizan Abbas FMH College of Medicine and Dentistry, Lahore, Pakistan.
Zahra Nawaz CMH Lahore Medical and Dental College, Pakistan.
Muhammad Waseel Ahmad Jilin University, China/ Sir Gangaram Hospital Lahore, Pakistan.
Musab Binyameen Faculty of Pharmacy, Gomal University Dera Ismail Khan, KPK, Pakistan.

DOI:

https://doi.org/10.70749/ijbr.v3i4.991

Keywords:

Tumor Microenvironment, Cancer Progression, Therapeutic Resistance, Immune Cell Infiltration, Fibroblast Activity, ECM Remodeling, Chemotherapy, Immunotherapy, Personalized Cancer Therapy

Abstract

This study explores the critical role of the tumor microenvironment (TME) in cancer progression and therapeutic resistance, aiming to provide insights into novel treatment strategies targeting the TME. Using a quantitative research design, both in vitro and in vivo experiments were conducted, coupled with clinical data analysis from 92 patients diagnosed with breast, colon, and lung cancer. The methodology involved collecting tumor tissue samples, patient clinical records, and analyzing immune cell infiltration, fibroblast activity, and ECM remodeling within the TME. Multivariate regression analysis, Kaplan-Meier survival analysis, and Chi-Square tests were employed to examine the relationship between TME characteristics and patient survival. The results revealed that high immune cell infiltration was significantly associated with improved survival, while extensive ECM remodeling was linked to poorer survival outcomes. Treatment strategies, particularly chemotherapy and immunotherapy, demonstrated substantial improvements in patient response, with immunotherapy showing the strongest correlation with survival. This research emphasizes the critical role of the tumor microenvironment (TME) in cancer progression and treatment resistance. Key TME components—immune cells, fibroblasts, and extracellular matrix (ECM) remodeling—significantly impact patient outcomes. Elevated immune infiltration improves survival, while excessive ECM remodeling predicts poor prognosis. Combining traditional therapies like chemotherapy with immunotherapy or TME-targeting drugs offers promising individualized approaches. Future research should focus on personalized strategies tailored to a patient’s TME profile, with real-time monitoring guiding adaptive treatments. Novel agents targeting fibroblasts or ECM and advancements like 3D organoids or PDX models will enhance therapeutic testing. Multidisciplinary efforts are vital to translate these insights into clinical success and to overcome therapy resistance through TME-targeted interventions.

Downloads

Download data is not yet available.

References

Sun, Y., Tumor microenvironment and cancer therapy resistance. Cancer letters, 2016. 380(1): p. 205-215. https://doi.org/10.1016/j.canlet.2015.07.044

Son, B., et al., The role of tumor microenvironment in therapeutic resistance. Oncotarget, 2016. 8(3): p. 3933. https://doi.org/10.18632/oncotarget.13907

Neophytou, C.M., et al., The role of tumor microenvironment in cancer metastasis: Molecular mechanisms and therapeutic opportunities. Cancers, 2021. 13(9): p. 2053. https://doi.org/10.3390/cancers13092053

Fontana, F., M. Anselmi, and P. Limonta, Molecular mechanisms of cancer drug resistance: emerging biomarkers and promising targets to overcome tumor progression. 2022, MDPI. p. 1614. https://doi.org/10.3390/cancers14071614

Falcone, I., et al., Tumor microenvironment: Implications in melanoma resistance to targeted therapy and immunotherapy. Cancers, 2020. 12(10): p. 2870. https://doi.org/10.3390/cancers12102870

Yuan, Y., et al., Role of the tumor microenvironment in tumor progression and the clinical applications. Oncology reports, 2016. 35(5): p. 2499-2515. https://doi.org/10.3892/or.2016.4660

Desai, S.A., et al., The tumor microenvironment: shaping cancer progression and treatment response. Journal of Chemotherapy, 2025. 37(1): p. 15-44. https://doi.org/10.1080/1120009x.2023.2300224

Sherman, M.H. and G.L. Beatty, Tumor microenvironment in pancreatic cancer pathogenesis and therapeutic resistance. Annual Review of Pathology: Mechanisms of Disease, 2023. 18(1): p. 123-148. https://doi.org/10.1146/annurev-pathmechdis-031621-024600

Ramos, P. and M. Bentires-Alj, Mechanism-based cancer therapy: resistance to therapy, therapy for resistance. Oncogene, 2015. 34(28): p. 3617-3626. https://doi.org/10.1038/onc.2014.314

Box, C., et al. Tumour-microenvironmental interactions: paths to progression and targets for treatment. in Seminars in cancer biology. 2010. Elsevier. https://doi.org/10.1016/j.semcancer.2010.06.004

Goenka, A., et al., Tumor microenvironment signaling and therapeutics in cancer progression. Cancer Communications, 2023. 43(5): p. 525-561. https://doi.org/10.1002/cac2.12416

Sounni, N.E. and A. Noel, Targeting the tumor microenvironment for cancer therapy. Clinical chemistry, 2013. 59(1): p. 85-93. https://doi.org/10.1373/clinchem.2012.185363

Roma-Rodrigues, C., et al., Targeting tumor microenvironment for cancer therapy. International journal of molecular sciences, 2019. 20(4): p. 840. https://doi.org/10.3390/ijms20040840

Mehraj, U., et al., The tumor microenvironment as driver of stemness and therapeutic resistance in breast cancer: New challenges and therapeutic opportunities. Cellular Oncology, 2021: p. 1-21. https://doi.org/10.1007/s13402-021-00634-9

Kilmister, E.J., et al., Cancer metastasis and treatment resistance: Mechanistic insights and therapeutic targeting of cancer stem cells and the tumor microenvironment. Biomedicines, 2022. 10(11): p. 2988. https://doi.org/10.3390/biomedicines10112988

Mittal, S., N.J. Brown, and I. Holen, The breast tumor microenvironment: role in cancer development, progression and response to therapy. Expert review of molecular diagnostics, 2018. 18(3): p. 227-243. https://doi.org/10.1080/14737159.2018.1439382

Junttila, M.R. and F.J. De Sauvage, Influence of tumour micro-environment heterogeneity on therapeutic response. Nature, 2013. 501(7467): p. 346-354. https://doi.org/10.1038/nature12626

Dzobo, K., D.A. Senthebane, and C. Dandara, The tumor microenvironment in tumorigenesis and therapy resistance revisited. Cancers, 2023. 15(2): p. 376. https://doi.org/10.3390/cancers15020376

El-Tanani, M., et al., Unraveling the tumor microenvironment: Insights into cancer metastasis and therapeutic strategies. Cancer Letters, 2024: p. 216894. https://doi.org/10.1016/j.canlet.2024.216894

Klemm, F. and J.A. Joyce, Microenvironmental regulation of therapeutic response in cancer. Trends in cell biology, 2015. 25(4): p. 198-213. https://doi.org/10.1016/j.tcb.2014.11.006

Barker, H.E., et al., The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nature Reviews Cancer, 2015. 15(7): p. 409-425. https://doi.org/10.1038/nrc3958

Ashrafi, A., et al., Current landscape of therapeutic resistance in lung cancer and promising strategies to overcome resistance. Cancers, 2022. 14(19): p. 4562. https://doi.org/10.3390/cancers14194562

Nallasamy, P., et al., Tumor microenvironment enriches the stemness features: the architectural event of therapy resistance and metastasis. Molecular cancer, 2022. 21(1): p. 225. https://doi.org/10.1186/s12943-022-01682-x

Santos, P. and F. Almeida, Role of exosomal miRNAs and the tumor microenvironment in drug resistance. Cells, 2020. 9(6): p. 1450. https://doi.org/10.3390/cells9061450

Trédan, O., et al., Drug resistance and the solid tumor microenvironment. Journal of the National Cancer Institute, 2007. 99(19): p. 1441-1454. https://doi.org/10.1093/jnci/djm135

Seebacher, N.A., et al., Tumour microenvironment stress promotes the development of drug resistance. Antioxidants, 2021. 10(11): p. 1801. https://doi.org/10.3390/antiox10111801

Marine, J.-C., S.-J. Dawson, and M.A. Dawson, Non-genetic mechanisms of therapeutic resistance in cancer. Nature Reviews Cancer, 2020. 20(12): p. 743-756. https://doi.org/10.1038/s41568-020-00302-4

Senthebane, D.A., et al., The role of tumor microenvironment in chemoresistance: to survive, keep your enemies closer. International journal of molecular sciences, 2017. 18(7): p. 1586. https://doi.org/10.3390/ijms18071586

Meng, L., et al., The tumor microenvironment: a key player in multidrug resistance in cancer. Oncologie, 2024. 26(1): p. 41-58. https://doi.org/10.1515/oncologie-2023-0459

Chaudhary, B. and E. Elkord, Regulatory T cells in the tumor microenvironment and cancer progression: role and therapeutic targeting. Vaccines, 2016. 4(3): p. 28. https://doi.org/10.3390/vaccines4030028

Lovly, C.M. and A.T. Shaw, Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies. Clinical Cancer Research, 2014. 20(9): p. 2249-2256. https://doi.org/10.1158/1078-0432.ccr-13-1610

Gajewski, T.F., et al., Immune resistance orchestrated by the tumor microenvironment. Immunological reviews, 2006. 213(1): p. 131-145. https://doi.org/10.1111/j.1600-065x.2006.00442.x

Hirata, E. and E. Sahai, Tumor microenvironment and differential responses to therapy. Cold Spring Harbor perspectives in medicine, 2017. 7(7): p. a026781. https://doi.org/10.1101/cshperspect.a026781

Cosentino, G., et al., Breast cancer drug resistance: overcoming the challenge by capitalizing on MicroRNA and tumor microenvironment interplay. Cancers, 2021. 13(15): p. 3691. https://doi.org/10.3390/cancers13153691

Bayat, M. and J.S. Nahand, Battlegrounds of treatment resistance: decoding the tumor microenvironment. Naunyn-Schmiedeberg's Archives of Pharmacology, 2025: p. 1-19. https://doi.org/10.1007/s00210-025-04055-5

Kharaishvili, G., et al., The role of cancer-associated fibroblasts, solid stress and other microenvironmental factors in tumor progression and therapy resistance. Cancer cell international, 2014. 14: p. 1-8. https://doi.org/10.1186/1475-2867-14-41

Somasundaram, R., M. Herlyn, and S.N. Wagner, The role of tumor microenvironment in melanoma therapy resistance. Melanoma management, 2016. 3(1): p. 23-32. https://doi.org/10.2217/mmt.15.37

Kundu, M., et al., Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer. Molecular Cancer, 2024. 23(1): p. 92. https://doi.org/10.1186/s12943-024-01990-4

Chand, S., et al., The landscape of pancreatic cancer therapeutic resistance mechanisms. International journal of biological sciences, 2016. 12(3): p. 273. https://doi.org/10.7150/ijbs.14951

Rapisarda, A. and G. Melillo, Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies. Drug Resistance Updates, 2009. 12(3): p. 74-80. https://doi.org/10.1016/j.drup.2009.03.002